Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Regulation of cell identify through epigenetic modifications
- Chromatin compaction structurally organizes DNA
- Chromatin structure and epigenetic information
- Chromatin structure impacts gene regulation
- Chromatin dysregulation in cancer
- Epigenetic changes in cancer - tumor suppressor genes
- Epigenetic changes in cancer - oncogene
- DNA methylation changes in cancer
- Targeting DNA methylation in cancer
- Mutation of epi-regulators alters chromatin state
- Dysregulated components of epigenetic information: modifications of histone tails
- Dysregulated components of epigenetic information: chromatin readers
- Dysregulated components of epigenetic information: chromatin remodeling
- Histone acetylation changes in cancer
- Targeting histone acetylation in cancer: HDACs
- Targeting histone acetylation in cancer: HATs
- Histone methylation changes in cancer
- Histone methylation changes in cancer: EZH2
- Histone methylation changes in cancer: DOT1L
- Targeting histone methylation in cancer: HMTs
- Histone methylation changes in cancer: LSD1
- Targeting histone methylation in cancer: HDMs
- Targeting chromatin reader proteins in cancer
- Targeting BET-family bromodomains in cancer
- Clinical application of epigenetic drugs
- Epigenetic drug discovery and the road ahead
- Thank you
Topics Covered
- Chromatin dysregulation in cancer
- Features of epigenetic information in cells
- Mutated chromatin regulatory factors as tumor drivers
- Therapeutic rationale for the use of epigenetic drugs in oncology
- First generation epigenetic drugs: DNMT and HDAC inhibitors
- Novel therapeutic discoveries in oncology
- Biomarkers for patient selection
Talk Citation
Paul, T. (2021, January 31). Cancer-specific epigenetic alterations as investigated from a pharmaceutical perspective [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/GNWB8289.Export Citation (RIS)
Publication History
Financial Disclosures
- Commercial matters disclosed are that Dr Thomas Paul is a current employee of Pfizer, Inc.
Cancer-specific epigenetic alterations as investigated from a pharmaceutical perspective
Published on January 31, 2021
34 min
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Thomas Paul,
and I'm the Director of the Cancer Epigenetics Group at Pfizer Oncology,
located in San Diego, California.
Our group at Pfizer has been involved in the development of
small-molecule inhibitors to therapeutically target cancer epigenetic mechanisms.
For the topic of today's talk,
I'm going to give the perspective of a person in
the pharmaceutical industry in terms of how we're thinking about targeting
cancer epigenetics and doing so by understanding the roles of epigenetics and
the dysregulation of epigenetics that appears to be
an important part of the development of human cancer.
0:37
Before we consider the role of epigenetics in cancer,
I think it's a good idea to step back and discuss some of the fundamental roles
that epigenetics plays in the regulation of cell identity.
If we consider that essentially every cell in the human body
possesses similar DNA content and similar DNA sequence,
we have to understand that this one style or one genome can give rise to
this really huge diversity in cell types and cell behaviors that we appreciate,
comprises all the tissues and organs in the human body.
It's clear that there really needs to be a separate layer of information
stored in cells that really provides the ability of cells
to change their DNA sequence or their genotype into
these diverse phenotypes that we appreciate in all these different cell types.
Also, if we consider that there's really
some pretty sophisticated structures that evolve in the human body,
in different tissues and organs,
and we understand that these organs are comprised of many different cells,
all of which interact with each other.
Then, we understand that these tissues have to organize themselves through
many types of cell divisions and cell cycles of mitosis.
Through this, these cells need to remember
their cell identity and their cell behavior over multiple generations,
in such a way that these tissues and organs become properly organized.
Again, there needs to be some level of ability of cells to remember who they are,
where they came from, and how they should behave.
Really this concept or this stable and inheritable layer of
cellular information really forms what is
understood to be the fundamental basis of what is epigenetics.
For today's talk, what I'll be covering are some of the key components
of the cell that make up this layer of epigenetic information,
and I'll be discussing how epigenetic changes are
commonly occurring in cancer and how this is really important
for impacting the cell identity that really changes
the cell behavior that we appreciate as
a common event in the development of human cancer.
Hide